Gynecomastia Extension Study

AstraZeneca

Overview

The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another anastrozole study).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Gynecomastia

Interventions

AnastrozoleDRUG

Eligibility

Sex: MALEMin age: 11 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must have entered Trial 1033US/0006 and completed 6 months of treatment and one month of follow-up. * Subjects must have gynecomastia, with one breast measuring at least 3 cm in diameter. Exclusion Criteria: * Subjects who have been given medications known to cause gynecomastia within the previous 3 months

Outcomes

Primary Outcomes

Change in linear dimensions of the breast

Secondary Outcomes

Change in breast tenderness

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.